Skip to main content
. 2023 Jun 14;15(12):3179. doi: 10.3390/cancers15123179

Figure 9.

Figure 9

Immunohistochemistry of PDX tumors treated with tamoxifen or combination therapy. (A) HER2 IHC staining of 5 orthotopic ER+ PDX models with and without treatment with tamoxifen in vivo. (B) H&E, Ki67, and HER2 staining of HCI-011 mammary tumors from mice treated with tamoxifen combination therapies, and the quantification of positive nuclei or positive area (D). (C) H&E, Ki67, and HER2 staining of BCM-15057 mammary tumors from mice treated with tamoxifen combination therapies, and the quantification of positive nuclei or positive area (E). All images of IHC have been taken at 400× magnification.